Phase-II trial of rituximab in patients with relapsed CD20-positive Hodgkin's lymphoma: An update from the German Hodgkin's Lymphoma Study Group (GHSG).

被引：0
|
作者：
Schulz, H
Rehwald, U
Reiser, M
Ruediger, T
Morschhauser, F
Diehl, V
Engert, A
机构：
[1] Univ Cologne, Dept Internal Med 1, D-5000 Cologne 41, Germany
[2] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[3] Ctr Hosp Reg & Univ Lille, F-59037 Lille, France
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3066
引用
收藏
页码：775A / 775A
页数：1
相关论文
共 50 条
  • [41] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Kuruvilla, John
    Taylor, Diane
    Wang, Lisa
    Blattler, Chantale
    Keating, Armand
    Crump, Michael
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [42] Clinical outcomes of relapsed Hodgkin lymphoma patients after contemporary first-line treatment: Results from the German Hodgkin Study Group (GHSG)
    Brockelmann, P.
    Muller, H.
    Gillessen, S.
    Yang, X.
    Koppel, L.
    Pilz, V
    Marinello, P.
    Kaskel, P.
    Raut, M.
    Fuchs, M.
    Borchmann, P.
    Engert, A.
    von Tresckow, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 37 - 37
  • [43] Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: An analysis from the German Hodgkin Study Group
    Klimm, B
    Reineke, T
    Haverkamp, H
    Behringer, K
    Eich, HT
    Josting, A
    Pfistner, B
    Diehl, V
    Engert, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 8003 - 8011
  • [44] Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group
    D A Eichenauer
    H Goergen
    A Plütschow
    D Wongso
    K Behringer
    S Kreissl
    I Thielen
    T Halbsguth
    P J Bröckelmann
    M Fuchs
    B Böll
    B von Tresckow
    P Borchmann
    A Engert
    Leukemia, 2016, 30 : 1425 - 1427
  • [45] Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group
    Eichenauer, D. A.
    Goergen, H.
    Pluetschow, A.
    Wongso, D.
    Behringer, K.
    Kreissl, S.
    Thielen, I.
    Halbsguth, T.
    Broeckelmann, P. J.
    Fuchs, M.
    Boell, B.
    von Tresckow, B.
    Borchmann, P.
    Engert, A.
    LEUKEMIA, 2016, 30 (06) : 1425 - 1427
  • [46] Fertility in male patients with Hodgkin's disease results from the German Hodgkin Lymphoma Study Group
    Sieniawski, M
    Josting, A
    Reineke, T
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 : 118 - 118
  • [47] Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Goergen, Helen
    Pluetschow, Annette
    Behringer, Karolin
    Kreissl, Stefanie
    Broeckelmann, Paul
    Fuchs, Michael
    Boell, Boris
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2015, 126 (23)
  • [48] Secondary malignancies after primary Hodgkin's disease: Incidence, treatment and prognosis - A report from the German Hodgkin's lymphoma study group (GHSG)
    Engert, A
    Josting, A
    Wingbermuehle, K
    Behringer, K
    Brillant, C
    Pfistner, B
    Sieber, M
    Rueffer, U
    Franklin, J
    Wolf, J
    Mueller, RP
    Diehl, V
    BLOOD, 2002, 100 (11) : 280B - 280B
  • [49] Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma:: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
    Josting, A
    Rudolph, C
    Mapara, M
    Glossmann, JP
    Sienawski, M
    Sieber, M
    Kirchner, HH
    Dörken, B
    Hossfeld, DK
    Kisro, J
    Metzner, B
    Berdel, WE
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 116 - 123
  • [50] Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma:: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
    Josting, A
    Haverkamp, H
    Raemackers, J
    Diehl, V
    Dörken, B
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 : 302 - 302
12345